The Australian Therapeutic Goods Administration (TGA) has updated its product warnings on the class of weight loss and ...

Public interest in drugs known as glucagon-like peptide-1 receptor agonists, also called GLP-1 RAs, has surged in recent ...

They’re definitely easier and more affordable than injectables, but do they work as well? Here’s what you need to know.

User engagement in a digital weight-loss program yielded better results in participants taking GLP-1 receptor agonists than ...

Amid soaring global demand for glucagon-like peptide-1 (GLP-1) medications and widespread concerns about affordability and access, the World Health Organization (WHO) released its global comprehensive ...

In addition to reducing hunger, popular weight-loss drugs also affect reward processing and motivated behaviors.

A rare intracranial brain-recording study revealed that tirzepatide, a GLP-1 and GIP receptor agonist, temporarily silences craving-related neural activity in a key reward circuit of the brain.

In SURPASS-PEDS, Mounjaro met the primary and all key secondary endpoints at 30 weeks and showed sustained improvement in glycemic control and continued BMI reduction through the study's 52-week ...

Drugs that bind to and activate the receptors for the hormones GLP-1 and GIP are effective in the treatment of obesity and diabetes. Surprisingly, active substances are currently being developed that ...

Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes medications — also known as GLP-1 and GIP injections — are changing the way we ...

The guideline specifies that drugs alone are not enough and emphasizes the need for behavioral and lifestyle interventions.

BERLIN — A novel glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor dual agonist combined into a single drug (LY3298176, Lilly), dubbed a "twincretin," ...